Dongkwan Jin
Neurology · Lubbock, TXNPI 1508310111
Payments from drug & device makers
Across 162 payments — averaging $26.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$1K
- AbbVie$512
- UCB, Inc.$422
- Lilly USA, LLC$213
- AstraZeneca$191
- MDD US Operations, LLC$190
- plus $2K from 26 others
What the payments were for
- Travel & lodging$73917%
- Food & beverage$3,49280%
- Education$1173%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 14 | $1,028 |
| AbbVie(2 entities) | 26 | $512 |
| UCB, Inc. | 20 | $422 |
| Lilly USA, LLC | 12 | $213 |
| AstraZeneca | 8 | $191 |
| MDD US Operations, LLC | 7 | $190 |
| Pfizer | 9 | $164 |
| SK Life Science, Inc. | 6 | $151 |
| Novartis | 7 | $136 |
| EMD Serono, Inc. | 3 | $128 |
| Teva Pharmaceuticals USA, Inc. | 3 | $125 |
| Sanofi | 2 | $118 |
| Argenx US, Inc. | 4 | $103 |
| Eisai Inc. | 5 | $80 |
| Amgen | 3 | $76 |
| Neurocrine Biosciences, Inc. | 3 | $74 |
| Genentech USA, Inc. | 3 | $73 |
| Lundbeck LLC | 4 | $72 |
| Cala Health, Inc. | 2 | $64 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $56 |
| CSL Behring | 2 | $51 |
| Amneal Pharmaceuticals LLC | 2 | $49 |
| Tanabe Pharma America, Inc. | 3 | $48 |
| Insightec,inc | 1 | $47 |
| Kyowa Kirin, Inc. | 2 | $36 |
| Biogen | 2 | $36 |
| Livanova USA, Inc. | 1 | $21 |
| Merz Pharmaceuticals, LLC | 1 | $20 |
| Otsuka America Pharmaceutical, Inc. | 1 | $16 |
| Banner Life Sciences, LLC | 1 | $16 |
| Acadia Pharmaceuticals Inc | 1 | $16 |
| Acorda Therapeutics, Inc | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INFINITY$839
How this compares
$4,348 in reported general payments places this provider in the 55th percentile of 1,246 neurology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| NuplazidPimavanserin Tartrate | 47 | $233,157 |
| OctagamImmun Globg(Igg)/Malt/Iga Ov50 | 13 | $158,124 |
| Kesimpta PenOfatumumab | 14 | $139,207 |
| AustedoDeutetrabenazine | 12 | $91,400 |
| Aimovig AutoinjectorErenumab-Aooe | 54 | $52,695 |
| BotoxOnabotulinumtoxina | 28 | $51,263 |
| Emgality PenGalcanezumab-Gnlm | 31 | $44,407 |
| RytaryCarbidopa/Levodopa | 34 | $42,380 |
| Nurtec OdtRimegepant Sulfate | 18 | $24,815 |
| BriviactBrivaracetam | 16 | $23,780 |
| FycompaPerampanel | 17 | $22,731 |
| XeominIncobotulinumtoxina | 15 | $22,510 |
| UbrelvyUbrogepant | 17 | $22,139 |
| Lamotrigine OdtLamotrigine | 19 | $11,041 |
| Emgality SyringeGalcanezumab-Gnlm | 11 | $7,582 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Acadia Pharmaceuticals IncNuplazid | $16 | $233,15747 claims |
| PfizerOctagam, Nurtec Odt | $164 | $182,93931 claims |
| Teva Pharmaceuticals USA, Inc.Austedo | $125 | $91,40012 claims |
| AbbVieBotox, Ubrelvy | $512 | $73,40245 claims |
| Amneal Pharmaceuticals LLCRytary, Pyridostigmine Bromide | $49 | $45,11561 claims |
| UCB, Inc.Briviact | $422 | $23,78016 claims |
| Eisai Inc.Fycompa | $80 | $22,73117 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 1,246 neurology providers in Texas.
Other neurology in Lubbock
- Bhupesh DiheniaLubbock$6.9M
- Mirla AvilaLubbock$1.3M
- Ahmad SabouniLubbock$737K
- Ann BassSan Antonio$12.3M
- Kandasami SenthilkumarBeaumont$7.6M
- Bharathy SundaramSherman$7.2M
- Jamshid LotfiHouston$6M
- Nazanin MajdHouston$5.9M
- Aziz ShaibaniHouston$5.5M
- Elizabeth PeckhamRound Rock$5.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.